PCRX Q1 2023 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$160M+1.5% YoY

Gross Profit

$111M69.4% margin

Operating Income

-$3M-1.9% margin

Net Income

-$20M-12.2% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-6.8%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$13M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$755M

Stockholders' Equity

$768M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$160M	$158M	+1.5%
Gross Profit	$111M	$122M	-8.7%
Operating Income	-$3M	$17M	-117.8%
Net Income	-$20M	$7M	-386.1%

Revenue Segments

Product

$159M51%

EXPAREL/bupivacaine liposome injectable suspension

$130M41%

ZILRETTA

$24M8%

Bupivacaine Liposome Injectable Suspension

$688,0000%